Dapagliflozin prevents kidney podocytes pyroptosis via miR-155-5p/HO-1/ NLRP3 axis modulation

被引:16
作者
Zhang, Zhen-Wang [1 ,2 ]
Tang, Ming-Qiu [3 ]
Liu, Wu [1 ,2 ]
Song, Yi [3 ]
Gao, Man-Jun [3 ]
Ni, Ping [4 ]
Zhang, Dan-Dan [1 ,2 ]
Mo, Qi-gui [1 ,2 ]
Zhao, Bao-Qing [1 ,2 ]
机构
[1] Hubei Univ Sci & Technol, Med Res Inst, Xianning 437000, Peoples R China
[2] Hubei Univ Sci & Technol, Hubei Key Lab Diabet & Angiopathy, Xianning 437000, Peoples R China
[3] Hubei Univ Sci & Technol, Sch Pharm, Xianning 437000, Peoples R China
[4] Hubei Univ Sci & Technol, Clin Med, Xianning 437000, Peoples R China
关键词
Diabetes mellitus; Pyroptosis; Dapagliflozin; miR-155-5p; HO-1; CELL-DEATH; INFLAMMASOME; DISEASE; ACTIVATION; CASPASES;
D O I
10.1016/j.intimp.2024.111785
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Diabetic nephropathy (DN) is a significant clinical microvascular complication associated with diabetes mellitus (DM), and end -stage diabetes giving rise to kidney failure is developing into the major etiological factor of chronic kidney failure. Dapagliflozin is reported to limit podocyte damage in DM, which has proven to protect against renal failure. Mounting evidence has demonstrated that pyroptosis is associated with DM progression. Nevertheless, whether pyroptosis causes DN and the underlying molecular pathways remain obscure. In this study, we aimed to explore the antipyroptotic attributes of dapagliflozin and elucidate the underlying mechanisms of kidney damage in diabetes. In vivo, experiments were conducted in streptozotocin (STZ)-induced type 2 diabetic mice, which were administered dapagliflozin via gavage for 6 weeks. Subsequently, the specific organizational characteristics and expression of pyroptosis-related genes were evaluated. Intragastric dapagliflozin administration markedly reduced renal tissue injury. Meanwhile, dapagliflozin also attenuated the expression level of pyroptosis associated genes, including ASC, cleaved Caspase-1, GSDMD N -termini, NLRP3, IL -18, and IL1 beta in renal tissue of dapagliflozin-treated animals. Similar antipyroptotic effects were observed in palmitic acid (PA) -treated mouse podocytes. We also found that heme oxygenase 1 (HO -1) enhanced the protection of mouse podocyte clone 5 cells (MPC5). Moreover, miR-155-5p inhibition increased pyroptosis in PA -treated MPC5 cells, suggesting that miR-155-5p acts as an endogenous stimulator that increases HO -1 expression and reduces pyroptosis. Hence, our findings imply that dapagliflozin inhibits podocyte pyroptosis via the miR-155-5p/HO-1/ NLRP3 axis in DM. Furthermore, dapagliflozin substitution may be regarded as an effective strategy for preventing pyroptosis in the kidney, including a therapeutic option for treating pyroptosis-related DN.
引用
收藏
页数:13
相关论文
共 69 条
[11]   Diabetes, metabolic disease, and telomere length [J].
Cheng, Feifei ;
Carroll, Luke ;
Joglekar, Mugdha, V ;
Januszewski, Andrzej S. ;
Wong, Kwun Kiu ;
Hardikar, Anandwardhan A. ;
Jenkins, Alicia J. ;
Ma, Ronald C. W. .
LANCET DIABETES & ENDOCRINOLOGY, 2021, 9 (02) :117-126
[12]   M2 macrophage-derived exosomes carry microRNA-148a to alleviate myocardial ischemia/reperfusion injury via inhibiting TXNIP and the TLR4/NF-κB/NLRP3 inflammasome signaling pathway [J].
Dai, Yuxiang ;
Wang, Shen ;
Chang, Shufu ;
Ren, Daoyuan ;
Shali, Shalaimaiti ;
Li, Chenguang ;
Yang, Hongbo ;
Huang, Zheyong ;
Ge, Junbo .
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2020, 142 :65-79
[13]   Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers [J].
Dekkers, Claire C. J. ;
Petrykiv, Sergei ;
Laverman, Gozewijn D. ;
Cherney, David Z. ;
Gansevoort, Ron T. ;
Heerspink, Hiddo J. L. .
DIABETES OBESITY & METABOLISM, 2018, 20 (08) :1988-1993
[14]   Dapagliflozin: A Review in Type 2 Diabetes [J].
Dhillon, Sohita .
DRUGS, 2019, 79 (10) :1135-1146
[15]   Far-red acclimating cyanobacterium as versatile source for bright fluorescent biomarkers [J].
Ding, Wen-Long ;
Hou, Ya-Nan ;
Tan, Zi-Zhu ;
Jiang, Su-Ping ;
Miao, Dan ;
Losi, Aba ;
Gaertner, Wolfgang ;
Scheer, Hugo ;
Zhao, Kai-Hong .
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 2018, 1865 (11) :1649-1656
[16]   Dapagliflozin, an SGLT2 inhibitor, ameliorates acetic acid-induced colitis in rats by targeting NFκB/AMPK/NLRP3 axis [J].
El-Rous, Magdy Abou ;
Saber, Sameh ;
Raafat, Eman M. ;
Ahmed, Amany A. E. .
INFLAMMOPHARMACOLOGY, 2021, 29 (04) :1169-1185
[17]   Role of sodium glucose cotransporter type 2 inhibitors dapagliflozin on diabetic nephropathy in rats; Inflammation, angiogenesis and apoptosis [J].
Elkazzaz, Shimaa K. ;
Khodeer, Dina M. ;
El Fayoumi, Hassan M. ;
Moustafa, Yasser M. .
LIFE SCIENCES, 2021, 280
[18]   Bilirubin in clinical practice: a review [J].
Fevery, Johan .
LIVER INTERNATIONAL, 2008, 28 (05) :592-605
[19]   Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study [J].
Fioretto, Paola ;
Del Prato, Stefano ;
Buse, John B. ;
Goldenberg, Ronald ;
Giorgino, Francesco ;
Reyner, Daniel ;
Langkilde, Anna Maria ;
Sjostrom, C. David ;
Sartipy, Peter .
DIABETES OBESITY & METABOLISM, 2018, 20 (11) :2532-2540
[20]   Mechanistic insights into the amelioration effects of lipopolysaccharide-induced acute lung injury by baicalein: An integrated systems pharmacology study and experimental validation [J].
Gao, Zhi-dan ;
Yan, Hai-dong ;
Wu, Ning-hua ;
Yao, Qing ;
Wan, Bin-bin ;
Liu, Xiu-fen ;
Zhang, Zhen-wang ;
Chen, Qing-jie ;
Huang, Cui-ping .
PULMONARY PHARMACOLOGY & THERAPEUTICS, 2022, 73